| Nurix Therapeutics, Inc. (NRIX) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q3-CY2026 | Q2-CY2026 | Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | |
| Balance Sheet Date | 2026-May-31 | 2026-Feb-28 | 2025-Nov-30 | 2025-Aug-31 | 2025-May-31 | 2025-Feb-28 | 2024-Nov-30 | 2024-Aug-31 | 2024-May-31 | 2024-Feb-29 | 2023-Nov-30 | 2023-Aug-31 | 2023-May-31 | 2023-Feb-28 | 2022-Nov-30 | 2022-Aug-31 | 2022-May-31 | 2022-Feb-28 | 2021-Nov-30 | 2021-Aug-31 | 2021-May-31 | 2021-Feb-28 | 2020-Nov-30 | 2020-Aug-31 | |||||||||||||||||||||||||
| Fiscal Period | Q2-FY2026 | Q1-FY2026 | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | |||||||||||||||||||||||||
| Price to Sales | 64.88x | 68.18x | 22.19x | 17.43x | 8.45x | 9.82x | 15.99x | 24.48x | 25.70x | 16.44x | 8.88x | 6.51x | 5.52x | 7.77x | 10.05x | 13.39x | 15.61x | 14.74x | 18.19x | 43.41x | 45.88x | 51.62x | 60.54x | 71.65x | |||||||||||||||||||||||||
| Price to Book | 5.92x | 6.23x | 3.31x | 2.72x | 1.90x | 1.94x | 1.88x | 2.53x | 3.85x | 2.76x | 4.26x | 2.50x | 1.62x | 1.82x | 1.53x | 1.70x | 1.79x | 2.14x | 2.04x | 3.77x | 3.55x | 2.97x | 4.48x | 4.40x | |||||||||||||||||||||||||
| Price to Earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||
| Price to Unlevered FCF | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||
| Debt to Asset Ratio | .25x | .24x | .22x | .29x | .24x | .22x | .21x | .27x | .27x | .46x | .44x | .24x | .26x | .26x | .27x | .25x | .32x | .30x | .28x | .24x | .23x | .32x | .27x | .25x | 1.22x | ||||||||||||||||||||||||
| Current Ratio | 6.34x | 6.01x | 7.02x | 5.35x | 6.82x | 6.26x | 6.46x | 5.28x | 5.57x | 2.86x | 3.40x | 4.36x | 4.01x | 4.44x | 4.51x | 5.26x | 4.22x | 4.25x | 4.70x | 7.07x | 8.46x | 6.48x | 6.70x | 8.88x | 2.44x | ||||||||||||||||||||||||